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Immunotherapy utilizing chimeric antigen receptor (CAR) T cells is a promising strategy for the treatment of 
several types of cancer. Many preclinical and clinical studies engineer CAR T cells through a viral vector, 
presenting the potential for genotoxicity or insertional mutagenesis. We propose a 14-day non-viral process 
where we introduce the gene of interest via electroporation; integration can be achieved with the Sleeping 
Beauty transposon system. Minicircle (MC) DNA constructs containing the CAR, a surface marker (EGFRt), and 
a double mutant of dihydrofolate reductase (DHFRdm) are electroporated into previously frozen, unstimulated 
CD4/CD8 T cells with an RNA construct coding for the Sleeping Beauty transposase. After electroporation, cells 
are bead-stimulated with CD3/CD28 without the use of feeder cells throughout the process. CAR+ cells 
expressing DHFRdm are rendered insensitive to an FDA-approved small molecule drug, methotrexate (MTX), 
which allows for chemical selection of the cells of interest while avoiding a magnetic bead sort. The entire 
process is completed in 2 weeks with a media formulation that contains a serum-free replacement. 
 
First, we standardized electroporation conditions and observed that lower DNA concentrations resulted in lower 
basal levels of integration within T cells based on flow cytometry. Conversely, increased cell concentrations did 
not necessarily result in higher proportions of transgene positive cells. We also found that altering the 
concentration of MTX for chemical selection can select for cells that have a higher level of expression of the 
gene of interest based on MFI. Using this 14-day process and chemical selection, we were able to reach purities 
of >90% CD19CAR+ T cells where the majority of cells at the end of culture were of a minimally differentiated 
phenotype, expressing both CD45RA and CD62L. Preliminary characterization of metabolic phenotype showed 
that at the end of the 14-day process, cells were able to maintain a spare respiratory capacity with or without 
MTX selection. Initial studies showed that CD19CAR+ cells were able to produce cytokines in response to 
antigen-expressing target cells; preliminary analysis showed CAR+ cells respond markedly by the production of 
IFNγ alone or in combination with TNFα. CAR+ cells expressed the degranulation marker CD107a specifically in 
response to target antigen or TCR stimulation. We propose this process as a means to shorten the timeline and 
cost for production by using a nonviral method to engineer CAR T cells, avoid the use of feeder cells, and 
chemically select for cells of interest. Ultimately, this workflow is also applicable to CARs of any specificity and 




Figure 1. Schematic of 14-day 
nonviral process of CAR T cell 
production. Prior to starting a 
manufacturing process, T cells are 
isolated from a leukapheresis 
product and cryopreserved. Thaw, 
electroporation, and stimulation of 
the primary T cells occurs on day 
0, where cells are electroporated 
with CAR-containing MC 
constructs that will be integrated 
into the genome by the SB 
transposase RNA. Chemical 
selection begins on day 2 of the 
process and occurs through the 
remaining 12 days, with a bead 
removal step at day 7. On day 14, 
cells are characterized and then 
cryopreserved for later studies. 
